Table 5.
Cell line | Conc. (μg/mL) | % Inhibition | |
---|---|---|---|
β-amyrin acetate (1) | Scopoletin (4) | ||
HepG2 | 20 | 12.1 ± 3.4 | 11.4 ± 2.1 |
10 | 16.0 ± 0.3 | 6.5 ± 1.2 | |
5 | 20.4 ± 2.3 | 0.9 ± 0.1 | |
2.5 | 8.23 ± 0.7 | 5.9 ± 1.2 | |
MDA-MB-231 | 20 | −19.6 ± 1.2 | 8.2 ± 1.0 |
10 | −13.9 ± 1.2 | 6.0 ± 0.3 | |
5 | −5.5 ± 1.2 | 10.7 ± 9.8 | |
2.5 | 7.0 ± 0.1 | 15.5 ± 0.3 | |
A549 | 20 | 2.2 ± 0.5 | 7.9 ± 0.4 |
10 | 9.0 ± 1.0 | 14.9 ± 0.4 | |
5 | 10.8 ± 0.5 | 14.6 ± 0.5 | |
2.5 | 0.4 ± 0.7 | 14.3 ± 0.7 |
Results are presented as cell growth inhibition percentage at concentrations of 2.5 to 20 μg/mL, mean ± SD (n = 3). Doxorubicin was used as the positive control and exerted significant cell viability inhibitory effects against HepG2 (IC50 0.49 μg/mL), MDA-MB-231 (IC50 0.68 μg/mL)